PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33527177-3	2021	Upadacitinib is a once-daily, oral Janus kinase (JAK) inhibitor with increased selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2.	upadacitinib	0-12	Janus kinase 2	Homo sapiens	105-109	
34471993-11	2021	Simulations indicated that tofacitinib, upadacitinib, and baricitinib at steady state exhibited varying degrees of JAK 1/3 (daily average inhibition, 70-94%) and JAK 2/2 (23%-67%) inhibition at therapeutic concentrations, with Cmax values 17- to 33-fold lower than their TYK2 IC50 levels.	upadacitinib	40-52	Janus kinase 2	Homo sapiens	162-169	
34023008-1	2021	BACKGROUND: Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2.	upadacitinib	12-24	Janus kinase 2	Homo sapiens	111-115	
34023009-2	2021	Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermatitis.	upadacitinib	0-12	Janus kinase 2	Homo sapiens	99-103	
30394138-2	2019	Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects.	upadacitinib	0-12	Janus kinase 2	Homo sapiens	87-91	
31375130-9	2019	Notably, baricitinib inhibited JAK1/3 signaling to a lesser extent than upadacitinib and tofacitinib, while upadacitinib, baricitinib, and tofacitinib inhibited the signaling of JAK2/2-dependent cytokines, including GM-CSF and IL-3, as well as the signaling of the JAK2/TYK2-dependent cytokine G-CSF.	upadacitinib	108-120	Janus kinase 2	Homo sapiens	178-182	
32539713-5	2020	RESULTS: Treatment with JAKi (tofacitinib, baricitinib, upadacitinib) prevented GM-CSF-induced JAK2/STAT5 phosphorylation at higher concentrations (400 nM) in THP-1 cells.	upadacitinib	56-68	Janus kinase 2	Homo sapiens	95-99	
32539713-11	2020	Although baricitinib and upadacitinib almost completely blocked GM-CSF-mediated JAK2/STAT5 signaling, the inhibitory effects of tofacitinib were weaker at lower concentrations suggesting that variation exists among these JAKi in the inhibition of JAK2 signaling pathways.	upadacitinib	25-37	Janus kinase 2	Homo sapiens	80-84